MARKET

ATXS

ATXS

Astria Therapeutics Inc
NASDAQ
4.050
-0.320
-7.32%
Opening 11:00 05/13 EDT
OPEN
4.430
PREV CLOSE
4.370
HIGH
4.800
LOW
4.045
VOLUME
90.85K
TURNOVER
--
52 WEEK HIGH
12.92
52 WEEK LOW
3.555
MARKET CAP
228.56M
P/E (TTM)
-2.4130
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATXS last week (0505-0509)?
Weekly Report · 1d ago
Astria Therapeutics Inc <ATXS.OQ> expected to post a loss of 48 cents a share - Earnings Preview
Reuters · 05/05 11:08
Weekly Report: what happened at ATXS last week (0428-0502)?
Weekly Report · 05/05 11:06
Chord, InMode, Upstart, BridgeBio, Astria: Trending by Analysts
TipRanks · 05/03 09:01
Astria Therapeutics Publishes Navenibart Phase 1a Healthy Subject Results In Annals of Allergy, Asthma & Immunology
Benzinga · 05/01 12:12
Astria Therapeutics Price Target Announced at $47.00/Share by Cantor Fitzgerald
Dow Jones · 04/29 13:04
Astria Therapeutics initiated with an Overweight at Cantor Fitzgerald
TipRanks · 04/29 09:00
Weekly Report: what happened at ATXS last week (0421-0425)?
Weekly Report · 04/28 11:15
More
About ATXS
More
Astria Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Its lead product candidate is Navenibart, a potential monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, autosomal dominant genetic disorder. Its second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis (AD), an immune disorder associated with loss of skin barrier function and itching. It owns five patent families directed to navenibart. The first patent family is directed to the composition of matter of navenibart and its use in treating various plasma kallikrein associated disorders, including HAE. In the second patent family, it is directed to methods of treating various plasma-kallikrein-associated disorders, including HAE.
Recently
Symbol
Price
%Change

Webull offers Astria Therapeutics Inc stock information, including NASDAQ: ATXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATXS stock methods without spending real money on the virtual paper trading platform.